Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.
暂无分享,去创建一个
M. Blumenkranz | Joan W. Miller | P. Rosenfeld | J. Haller | S. Schwartz | Naveed B K Shams | J. Reimann | William L Greene | William L. Greene | Naveed B. K. Shams
[1] Ma Dong,et al. Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .
[2] G. Lang,et al. [Retinal angiomatous proliferation in age-related macular degeneration]. , 2006, Klinische Monatsblatter fur Augenheilkunde.
[3] P. Jong. Prevalence of age-related macular degeneration in the United States. , 2004 .
[4] Johanna M Seddon,et al. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. , 2003, Archives of ophthalmology.
[5] Seth M Steinberg,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.
[6] J. Jonas. VERTEPORFIN THERAPY OF SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: Meta-Analysis of 2-Year Safety Results in Three Randomized Clinical Trials: Treatment of Age-Related Macular Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy Study Report , 2002, American journal of ophthalmology.
[7] T. Cox,et al. Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration. , 2002, Archives of ophthalmology.
[8] Joan W. Miller,et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. , 2002, Archives of ophthalmology.
[9] S. Harding. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials¿TAP Report No. 5 , 2002 .
[10] Neil M Bressler,et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. , 2002, American journal of ophthalmology.
[11] J L Cleland,et al. Development of poly-(D,L-lactide--coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[12] Simon P. Harding,et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. , 2001, American journal of ophthalmology.
[13] G. Lip,et al. Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction. , 2001, Ophthalmology.
[14] N. Bressler,et al. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. , 1999, Archives of ophthalmology.
[15] J W Berger,et al. Age-related macular degeneration. , 2000, The New England journal of medicine.
[16] N. Ferrara,et al. Vascular endothelial growth factor and the regulation of angiogenesis. , 2000, Recent progress in hormone research.
[17] R. Cuthbertson,et al. Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of 125I-Labeled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal Administration , 1999, Toxicologic pathology.
[18] Leonard,et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.
[19] J. W. Miller. Vascular endothelial growth factor and ocular neovascularization. , 1997, The American journal of pathology.
[20] N. Ferrara,et al. The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.
[21] P. D. de Jong,et al. Increased expression of angiogenic growth factors in age-related maculopathy , 1997, The British journal of ophthalmology.
[22] Joan W. Miller,et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. , 1996, Archives of ophthalmology.
[23] E S Gragoudas,et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. , 1996, Archives of ophthalmology.
[24] L. Aiello,et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.
[25] Joan W. Miller,et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. , 1994, The American journal of pathology.
[26] J. Folkman,et al. Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes With Proliferative Diabetic Retinopathy , 1995 .
[27] F. Ferris,et al. Age-related macular degeneration and blindness due to neovascular maculopathy. , 1984, Archives of ophthalmology.
[28] M. Hogan,et al. Signs and symptoms of uveitis. I. Anterior uveitis. , 1959, American journal of ophthalmology.